Columbia University scientists found that a common antidepressant drug can speed up heart valve damage — but only in people who carry a specific gene variant, and only if their valve is already diseased.
Story Snapshot
- Researchers linked a gene variant called “long-long” 5-HTTLPR to faster mitral heart valve damage in patients who take antidepressants known as selective serotonin reuptake inhibitors (SSRIs).
- The study used 122 human heart valve tissue samples and mouse models to show how reduced serotonin transporter activity speeds up valve breakdown.
- The risk appears limited to patients who already have a degenerating mitral valve — healthy valves showed no negative effect.
- The researchers say a simple genetic screening test could one day help doctors identify which heart patients face higher risk from SSRIs.
What the Mitral Valve Does and Why This Matters
The mitral valve sits between two chambers on the left side of your heart. It opens and closes with every heartbeat to keep blood flowing the right way. When it breaks down — a condition called degenerative mitral regurgitation — blood leaks backward. Severe cases require open-heart surgery. Millions of people worldwide live with this condition, and doctors have long searched for clues about why some patients deteriorate faster than others.
A team led by Columbia University’s Department of Surgery, working with Children’s Hospital of Philadelphia, the University of Pennsylvania, and Valley Hospital Heart Institute, may have found one important clue. Their study was published in the journal Science Translational Medicine in January 2023 and was funded by the National Heart, Lung and Blood Institute. The answer involves serotonin — the same brain chemical targeted by the most commonly prescribed antidepressants in America.
How Serotonin Ends Up Damaging Heart Tissue
Serotonin does not just work in the brain. It also circulates in the bloodstream and interacts with heart tissue. Normally, a protein called the serotonin transporter — or SERT — clears serotonin away from heart valve cells before it can cause harm. But some people carry a gene variant that makes SERT less active. The researchers found that the “long” version of a gene region called 5-HTTLPR weakens SERT function. When a person inherits two copies of this variant — called the “long-long” genotype — SERT becomes significantly less effective.
With SERT running at low power, serotonin lingers near valve cells longer than it should. That extra exposure triggers the cells to produce too much collagen, a structural protein. Too much collagen stiffens and distorts the valve’s shape, making the leakage worse. The team confirmed this in 122 human mitral valve tissue samples and then replicated the effect in mice bred without a working SERT gene, as well as in normal mice treated with the SSRI fluoxetine. Both groups showed accelerated valve breakdown.
SSRIs Enter the Picture — With an Important Catch
SSRIs work by blocking SERT in the brain, which raises serotonin levels and helps relieve depression. That is exactly what makes this finding significant. In patients whose valves are already degenerating and who carry the “long-long” variant, adding an SSRI on top of an already-weakened SERT could push the system further toward damage. Clinical data from the study showed that “long-long” patients who took SSRIs needed valve surgery at a younger age than those who did not take SSRIs.
Here is the critical nuance the headlines often miss: the researchers found no harmful effect in patients with healthy mitral valves, even those with the “long-long” gene variant. The researchers themselves stated that low SERT activity alone is unlikely to cause valve degeneration from scratch. The risk appears to activate only once the valve has already started breaking down. This is not a reason for most SSRI users to panic — it is a reason for doctors to pay closer attention to a specific, identifiable group of patients.
What No One Is Doing Yet — and Should Be
The study authors suggest that checking a patient’s 5-HTTLPR genotype alongside their SSRI history could become a useful tool for managing heart valve disease risk. That is a reasonable, common-sense recommendation. A simple genetic screen could flag which patients with a deteriorating mitral valve need closer monitoring or a conversation about their antidepressant options. Yet no clinical guidelines currently require this screening before prescribing SSRIs. That gap is hard to justify given what this research shows.
No serious scientific counter-evidence has emerged to dispute Columbia’s core findings. No independent team has published a replication study using genotype-stratified data to challenge the results. The earlier Duke University research that found no link between SSRIs and valve disease did not separate patients by 5-HTTLPR genotype or pre-existing valve degeneration status — making it an apples-to-oranges comparison. Until a properly designed replication study appears, the Columbia findings stand as the most specific and well-supported evidence in this space. Patients with known mitral valve disease who take SSRIs deserve to know this research exists — and their doctors deserve the tools to act on it.
Sources:
sciencedaily.com, columbiasurgery.org, science.org, medicalxpress.com, ferrarilabcolumbia.com
